International drug regulators have reached a certain degree of alignment on key principles to support the use of adapted COVID-19 vaccines against Omicron variants of concern, but say that the development of such vaccines is made difficult by the rapid arrival of new variants.
“Current evidence is still evolving, and the situation is also very dynamic,” said Marco Cavaleri, head of biological health threats and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?